C4 Therapeutics (CCCC) Expected to Release Quarterly Earnings on Thursday

C4 Therapeutics (NASDAQ:CCCC) is projected to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.23) per share and revenue of $8.20 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 9:30 AM ET.

C4 Therapeutics (NASDAQ:CCCC) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.05. C4 Therapeutics had a negative net margin of 297.76% and a negative return on equity of 50.68%. The company had revenue of $6.15 million during the quarter, compared to the consensus estimate of $4.42 million. On average, analysts expect C4 Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

C4 Therapeutics Stock Performance

Shares of CCCC opened at $3.50 on Tuesday. C4 Therapeutics has a 52 week low of $1.69 and a 52 week high of $5.17. The stock has a market capitalization of $387.00 million, a price-to-earnings ratio of -2.94 and a beta of 2.91. The stock has a fifty day moving average of $3.94 and a 200-day moving average of $3.10.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of C4 Therapeutics in a research report on Friday, July 17th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, C4 Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $7.75.

Institutional Investors Weigh In On C4 Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CCCC. Virtu Financial LLC acquired a new position in C4 Therapeutics in the 4th quarter valued at approximately $39,000. Invesco Ltd. lifted its holdings in shares of C4 Therapeutics by 39.9% during the fourth quarter. Invesco Ltd. now owns 268,350 shares of the company’s stock worth $513,000 after purchasing an additional 76,530 shares during the period. Quadrature Capital Ltd bought a new stake in shares of C4 Therapeutics in the fourth quarter worth $254,000. Man Group plc grew its stake in shares of C4 Therapeutics by 72.9% in the fourth quarter. Man Group plc now owns 156,098 shares of the company’s stock worth $298,000 after purchasing an additional 65,820 shares during the last quarter. Finally, Engineers Gate Manager LP grew its stake in shares of C4 Therapeutics by 49.9% in the fourth quarter. Engineers Gate Manager LP now owns 24,416 shares of the company’s stock worth $47,000 after purchasing an additional 8,130 shares during the last quarter. 78.81% of the stock is owned by institutional investors.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.